PDF herunterladen
Drug Res (Stuttg) 2022; 72(06): 299-305
DOI: 10.1055/a-1813-9489
Original Article

Formulation, Characterization, and the Diuretic Effects of a New Intravenous Metolazone Emulsion

Kristen M. Ahlschwede
1   Department of Pharmaceutical Sciences, College of Pharmacy, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
,
Edward Ofori
2   Department of Pharmaceutical Sciences, College of Pharmacy, Chicago State University, Chicago, IL, USA
,
Terrick Andey
3   Department of Pharmaceutical Sciences, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Worcester, MA, USA.
,
Anita Osei
2   Department of Pharmaceutical Sciences, College of Pharmacy, Chicago State University, Chicago, IL, USA
,
John S Somberg
4   Department of Medicine, Rush University, Chicago, IL, USA.
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Objective Acute decompensated heart failure is often treated with a combination of loop and thiazide-like diuretics. Of these thiazide-like diuretics, two common choices are intravenous chlorothiazide or oral metolazone. Metolazone is more potent and has a longer duration of action, but since it is an oral formulation, it has a longer on-set time as compared to chlorothiazide. In addition, metolazone is poorly water-soluble, thereby rendering intravenous formulation more challenging. To address these issues, we proposed the formulation of a solvent-free metolazone emulsion for intravenous administration.

Methods An oil-in-water emulsion containing 1 mg/mL of metolazone was formulated by homogenizing soybean oil and l-lecithin in water in the presence of optimized concentrations of glycerin with tween 80 or poloxamer 188 as surfactant. The emulsion was characterized on the basis of particle size, zeta potential, morphology and metolazone release kinetics. The diuretic effect of the metolazone emulsion was evaluated in rats.

Results The 1 mg/mL metolazone emulsion prepared with 5% tween 80 displayed the best physical stability. The emulsion exhibited a hydrodynamic diameter of 157.13±1.52 nm. About 93% of metolazone was released from the formulation within 2 h. The 2 mg/kg and 4 mg/kg dose of the metolazone emulsion increased urine output in the rats by 68.9 and 134%, respectively, as compared to control rats. Furthermore, the 4 mg/kg dose exhibited a 168.8%, 25.8%, and 150.9% increase in sodium, potassium, and chloride, respectively.

Conclusion This metolazone emulsion was capable of increasing urine volume output and demonstrated both natriuretic and kaliuretic properties.

Key words

Metolazone - emulsion - intravenous - acute decompensated heart failure - diuretic


Publikationsverlauf

Eingereicht: 05. März 2022

Angenommen: 28. März 2022

Artikel online veröffentlicht:
10. Mai 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Joseph SM, Cedars AM, Ewald GA. et al. Acute decompensated heart failure: Contemporary medical management. Texas Hear Inst J 2009; 36: 510-520
    PubMedGoogle Scholar
  • 2 Moranville MP, Choi S, Hogg J. et al. Comparison of Metolazone Versus Chlorothiazide in Acute Decompensated Heart Failure with Diuretic Resistance. Cardiovasc Ther 2015; 33: 42-49
    CrossrefPubMedGoogle Scholar
  • 3 Mozaffarian D, Benjamin EJ, Go AS. et al. Heart disease and stroke statistics-2015 update : A report from the American Heart Association. Circulation 2015; 131: e29-e39
    PubMedGoogle Scholar
  • 4 Ambrosy AP, Fonarow GC, Butler J. C et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014; 63: 1123-1133
    CrossrefPubMedGoogle Scholar
  • 5 Heidenreich PA, Albert NM, Allen LA. et al. Forecasting the impact of heart failure in the united states a policy statement from the american heart association. Circ Hear Fail 2013; 6: 606-619
    CrossrefPubMedGoogle Scholar
  • 6 Hunt SA, Abraham WT, Chin MH. et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the Aamerican College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479
    PubMedGoogle Scholar
  • 7 Yancy CW, Jessup M, Bozkurt B. et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013; 62: e147-e239
    PubMedGoogle Scholar
  • 8 Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16: e1
    CrossrefPubMedGoogle Scholar
  • 9 Shulenberger CE, Jiang A, Devabhakthuni S. et al. Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. Pharmacotherapy 2016; 36: 852-860
    CrossrefPubMedGoogle Scholar
  • 10 Gong H, Geng S, Zheng Q. et al. An intravenous clarithromycin lipid emulsion with a high drug loading, H-bonding and a hydrogen-bonded ion pair complex exhibiting excellent antibacterial activity. Asian J Pharm Sci 2016; 11: 618-630
    CrossrefPubMedGoogle Scholar
  • 11 Kwasigroch B, Escribano E, Morán MdelC. et al. Oil-in-water nanoemulsions are suitable for carrying hydrophobic compounds: Indomethacin as a model of anti-inflammatory drug. Int J Pharm 2016; 515: 749-756
    CrossrefPubMedGoogle Scholar
  • 12 Kumar P, Nagarajan A, Uchil PD. Analysis of Cell Viability by the alamarBlue Assay. Cold Spring Harb Protoc 2018; 2018: 462-464
    PubMedGoogle Scholar
  • 13 Gonyon T, Carter PW, Trouilly JL. Conformance with USP chapter 729 for parenteral nutritional emulsions. Am J Heal Pharm 2008; 65: 1117-1118
    CrossrefPubMedGoogle Scholar
  • 14 Entegris, Inc. USP<729>Globule Size Distribution in Lipid Injectable Emulsions. n.d
    PubMed
  • 15 Lindquist DE, Rowe AS, Heidel E. et al. Evaluation of the Hemodynamic Effects of Intravenous Amiodarone Formulations During the Maintenance Phase Infusion. Ann Pharmacother 2015; 49: 1317-1321
    CrossrefPubMedGoogle Scholar
  • 16 Gupta V, Trivedi P. In vitro and in vivo characterization of pharmaceutical topical nanocarriers containing anticancer drugs for skin cancer treatment. Lipid Nanocarriers Drug Target., Elsevier; 2018, p. 563–627
    PubMed
  • 17 Samimi S, Maghsoudnia N, Eftekhari RB. et al. Lipid-Based Nanoparticles for Drug Delivery Systems. Charact Biol Nanomater Drug Deliv Nanosci Nanotechnol Drug Deliv 2019; 47-76
    PubMedGoogle Scholar
  • 18 Lockman PR, Koziara JM, Mumper RJ. et al. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target 2004; 12: 635-641
    CrossrefPubMedGoogle Scholar
  • 19 Ahlschwede KM, Curran GL, Rosenberg JT. et al. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer’s disease brain. Nanomedicine Nanotechnology, Biol Med. 2018
    PubMedGoogle Scholar
  • 20 Cvetanovic I, Ranade V, Molnar J. et al. The evaluation of the diuretic action of parenteral formulations of metolazone. Am J Ther 2007; 14: 25-29
    CrossrefPubMedGoogle Scholar
  • 21 Al Shoyaib A, Archie SR, Karamyan VT. Intraperitoneal route of drug administration: should it be used in experimental animal studies. Pharm Res 2020; 37: 12
    CrossrefPubMedGoogle Scholar
  • 22 Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother Pharmacol 1981; 54: 267-270
    CrossrefPubMedGoogle Scholar
  • 23 Guichard S, Chatelut E, Lochon I. et al. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 1998; 422: 165-170
    CrossrefPubMedGoogle Scholar
  • 24 Soma D, Kitayama J, Ishigami H. et al. Different Tissue Distribution of Paclitaxel With Intravenous and Intraperitoneal Administration. J Surg Res 2009; 155: 142-146
    CrossrefPubMedGoogle Scholar